| pioglitazone / Generic mfg. |
NCT00521742: Efficacy of Pioglitazone Compared to Glyburide in Treating Subjects With Type 2 Diabetes Mellitus and Mild Cardiac Disease |
|
|
| Completed | 3 | 300 | US | Pioglitazone, Actos, AD4833, Glyburide | Takeda, Takeda Pharmaceuticals North America, Inc. | Diabetes Mellitus | 01/03 | 01/03 | | |
NCT00521820: Safety Comparison of Pioglitazone and Glyburide in Type 2 Diabetes Subjects With Mild to Moderate Congestive Heart Failure |
|
|
| Terminated | 3 | 518 | US | Pioglitazone, Actos, AD-4833, Glyburide | Takeda | Diabetes Mellitus | 10/03 | 10/03 | | |
NCT00331487: Study to Compare Pioglitazone and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia |
|
|
| Completed | 3 | 719 | US | Pioglitazone, Actos, AD4833, Rosiglitazone | Takeda, Eli Lilly and Company | Diabetes Mellitus | 03/04 | 03/04 | | |
| Completed | 3 | 4373 | Europe | Pioglitazone, Actos, AD4833, Placebo | Takeda, Eli Lilly and Company | Diabetes Mellitus | 01/05 | 01/05 | | |
NCT00086502: Pioglitazone Add-on Study in Patients With Type 2 Diabetes Mellitus |
|
|
| Completed | 3 | 353 | US | Comparator: Sitagliptin, Januvia, Comparator: Placebo, Comparator: Pioglitazone, ACTOS, Metformin | Merck Sharp & Dohme LLC | Diabetes Mellitus, Type 2 | 11/05 | 11/05 | | |
| Completed | 3 | 527 | US | vildagliptin | Novartis Pharmaceuticals | Diabetes Mellitus, Type 2 | 01/06 | 01/06 | | |
NCT00106704: Sulfonylurea Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-035) |
|
|
| Completed | 3 | 441 | US | Comparator: Sitagliptin, Comparator: Placebo, Comparator: Pioglitazone | Merck Sharp & Dohme LLC | Diabetes Mellitus, Type 2 | 06/06 | 01/07 | | |
NCT00138554: Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes |
|
|
| Completed | 3 | 318 | US | vildagliptin, pioglitazone | Novartis | Diabetes Mellitus, Type 2 | 07/06 | 07/06 | | |
NCT00106808: Study of Muraglitazar Versus Pioglitazone in Type 2 Diabetes |
|
|
| Completed | 3 | 1440 | US, Canada, RoW | Muraglitazar, Pioglitazone | Bristol-Myers Squibb, Merck Sharp & Dohme LLC | Type 2 Diabetes Mellitus | 08/06 | 08/06 | | |
| Terminated | 3 | 1450 | US, Canada, Europe, RoW | Galida | AstraZeneca | Diabetes Mellitus, Type 2 | 10/06 | 10/06 | | |
| Terminated | 3 | 1100 | US, Canada, Europe, RoW | Tesaglitazar, Galida, Pioglitazone, Actos | AstraZeneca | Diabetes Mellitus, Type 2 | 12/06 | 12/06 | | |
| Completed | 3 | 588 | US, Europe | vildagliptin | Novartis | Diabetes Mellitus, Type 2 | 02/07 | | | |
| Completed | 3 | 2 | Europe | Pioglitazone, Placebo | University of Erlangen-Nürnberg Medical School | Hypertension, Diabetes Mellitus Type 2 | 03/07 | 01/11 | | |
NCT00376181: Efficacy, Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes Mellitus |
|
|
| Terminated | 3 | 96 | US, RoW | Pioglitazone and Azilsartan, Actos, AD-4833, TAK-536, Pioglitazone | Takeda | Type 2 Diabetes | 05/07 | 05/07 | | |
NCT01124656: Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes |
|
|
| Terminated | 3 | 26 | US | Pioglitazone-Azilsartan, Pioglitazone, Actos, Azilsartan, AD-4833, TAK-536 | Takeda | Diabetes Mellitus, Type 2 | 05/07 | 05/07 | | |
| Completed | 3 | 493 | US, Europe, RoW | Alogliptin and pioglitazone, SYR110322, Alogliptin, AD-4833, Pioglitazone, Actos, SYR-322 | Takeda | Diabetes Mellitus | 08/07 | 08/07 | | |
NCT00295633: A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone |
|
|
| Completed | 3 | 565 | US, Canada, RoW | Saxagliptin, BMS-477118, Placebo, pioglitazone, rosiglitazone, metformin | AstraZeneca | Diabetes Mellitus, Type 2 | 10/07 | 10/08 | | |
NCT00396227: Safety and Efficacy of Vildagliptin vs. Thiazolidinedione as add-on Therapy to Metformin in Patients With Type 2 Diabetes Not Controlled With Metformin Alone |
|
|
| Completed | 3 | 2665 | US | vildagliptin, Galvus, thiazolidinedione (TZD), Actos (pioglitazone), Avandia (rosiglitazone) | Novartis Pharmaceuticals | Diabetes Mellitus, Type 2 | 10/07 | | | |
| Completed | 3 | 655 | US, Europe, RoW | Alogliptin, SYR-322, Pioglitazone, Actos, AD4833, Placebo | Takeda | Diabetes Mellitus | 02/08 | 02/08 | | |
| Completed | 3 | 418 | Europe | Pioglitazone and Metformin, ACTOS®, AD4833, Metformin | Takeda | Diabetes Mellitus | 02/08 | 02/08 | | |
NCT00372060: MK0431 (Sitagliptin) Pioglitazone Add-on Study for Patients With Type 2 Diabetes Mellitus (0431-055)(COMPLETED) |
|
|
| Completed | 3 | 134 | Japan | sitagliptin phosphate, MK0431, Comparator: sitagliptin phosphate (MK0431), Comparator: pioglitazone, Comparator: placebo (unspecified) | Merck Sharp & Dohme LLC | Type 2 Diabetes Mellitus | 02/08 | 02/08 | | |
| Completed | 3 | 1554 | US, Europe, RoW | Alogliptin, SYR-322, Alogliptin placebo, Pioglitazone, ACTOS®, Pioglitazone placebo | Takeda | Type 2 Diabetes Mellitus | 03/08 | 03/08 | | |
|
|
NCT00411892: Effect of Inhaled Insulin (AERx® iDMS) on Blood Glucose Control in Type 2 Diabetes |
|
|
| Terminated | 3 | 196 | US | pioglitazone, inhaled human insulin, NN1998 | Novo Nordisk A/S | Diabetes, Diabetes Mellitus, Type 2 | 03/08 | 03/08 | | |
| Completed | 3 | 520 | US | sitagliptin 100 mg q.d./pioglitazone 30 mg q.d, Comparator: placebo to match sitagliptin 100 mg q.d./pioglitazone 30 mg q.d. | Merck Sharp & Dohme LLC | Type 2 Diabetes Mellitus | 06/08 | 06/08 | | |
| Completed | 3 | 91 | Europe | Pioglitazone and Glimepiride, ACTOS®, Glimepiride | Takeda | Diabetes Mellitus | 12/08 | 12/08 | | |
| Completed | 3 | 10251 | US, Canada | Anti-hyperglycemic Agents, glimepiride (Amaryl), metformin (Glucophage), repaglinide (Gluconorm, Prandin), rosiglitazone (Avandia), pioglitazone (Actos), human regular insulin (Novolin ge Toronto), human NPH (Novolin N), human mixed (Novolin 70/30), human isophane (Novolin ge NPH), human 30/70 (Novolin ge 30/70), insulin aspart (NovoRapid, NovoLog), insulin detemir (Levemir), human regular insulin (Novolin R), insulin glargine (Lantus), Acarbose, Anti-hypertensive Agents, benazepril (Lotensin, Zestril, Altace), chlorthalidone (Thalitone), metoprolol (Toprol XL), diltiazem (Tiazac), plendil (Felodipine), terazosin (Hytrin), candesartan (Atacand), valsartan (Diovan), furosemide, reserpine, hydralazine, carvedilol (Coreg), triamterene / hydrochlorothiazide (Dyazide), metoprolol / hydrochlorothiazide(Lopressor HCT), benazepril / hydrochlorothiazide (Lotensin HCT), lisinopril / hydrochlorothiazide (Zestoretic), candesartan / hydrochlorothiazide (Atacand HCT), valsartan / hydrochlorothiazide (Diovan HCT), amlodipine / benazepril (Lotrel), Blinded fenofibrate or placebo plus simvastatin, fenofibrate (Tricor) | National Heart, Lung, and Blood Institute (NHLBI), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Aging (NIA), National Eye Institute (NEI), Centers for Disease Control and Prevention | Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia, Hypertension, Diabetes Mellitus, Type 2, Diabetes Mellitus, Coronary Disease | 06/09 | 12/12 | | |
| Completed | 3 | 389 | Japan, Europe | placebo + pioglitazone (30 mg), Linagliptin + pioglitazone (30 mg) | Boehringer Ingelheim | Diabetes Mellitus, Type 2 | 06/09 | | | |
| Completed | 3 | 409 | Europe | Balaglitazone | Rheoscience A/S | Diabetes Mellitus, Type 2 | 07/09 | 10/09 | | |
| Completed | 3 | | Europe | pioglitazone | Technische Universität Dresden | Diabetes Mellitus, Kidney Transplantation, Proteinuria | 09/09 | 09/09 | | |
NCT00532935: MK0431A vs. Pioglitazone in Patients With Type 2 Diabetes Mellitus (0431A-066) |
|
|
| Completed | 3 | 517 | NA | sitagliptin phosphate (+) metformin hydrochloride, Janumet, Comparator: pioglitazone, pioglitazone | Merck Sharp & Dohme LLC | Type 2 Diabetes Mellitus | 10/09 | 10/09 | | |
| Completed | 3 | 597 | Europe, RoW | dapagliflozin, Glimepiride, Amaryl, metformin hydrochloride, Glucophage, pioglitazone hydrochloride, Actos, Rosiglitazone, Avandia | AstraZeneca, Bristol-Myers Squibb | Type 2 Diabetes | 11/09 | 05/10 | | |
|
|
|
|
|
| Completed | 3 | 71 | Europe | Alogliptin and Pioglitazone, alogliptin, SYR110322, Actos, AD-4833, SYR-322, Alogliptin, Placebo | Takeda | Diabetes Mellitus | 12/09 | 12/09 | | |
|
|
|
| Completed | 3 | 972 | US, Canada, RoW | Dapagliflozin, BMS-512148, Placebo matching Dapagliflozin, Thiazolidinedione (Pioglitazone) | AstraZeneca, Astra Zeneca, Bristol-Myers Squibb | Type 2 Diabetes | 01/10 | 06/10 | | |
|
|
|
NCT00541450: A Study to Evaluate the Efficacy and Safety of Sitagliptin and MK0431A in Comparison to a Commonly Used Medication in Patients With Type 2 Diabetes (0431-068)(COMPLETED) |
|
|
| Completed | 3 | 492 | US | Comparator: sitagliptin phosphate (sitagliptin), MK0431, Januvia™, sitagliptin phosphate (+) metformin hydrochloride, MK-0431A, Janumet™, Comparator: pioglitazone, Actos®, Matching placebo to pioglitazone, Matching placebo to sitagliptin, Matching Placebo to Sita/Met FDC | Merck Sharp & Dohme LLC | Type 2 Diabetes Mellitus | 01/10 | 01/10 | | |
|
|
| Completed | 3 | 602 | US | Pioglitazone, Actos, Placebo | The University of Texas Health Science Center at San Antonio, University of Texas, Takeda Pharmaceuticals North America, Inc. | Impaired Glucose Tolerance, Type 2 Diabetes | 04/10 | 04/10 | | |
|
|
|
NCT00970424 / 2009-012598-37: Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus (T2DM) on Background Therapy With Pioglitazone |
|
|
| Terminated | 3 | 252 | US, Europe, RoW | Placebo, Dutogliptin | Forest Laboratories, Phenomix | Diabetes Mellitus, Type II | 08/10 | | | |
| Completed | 3 | 447 | Europe, RoW | insulin degludec/insulin aspart, biphasic insulin aspart 30 | Novo Nordisk A/S | Diabetes, Diabetes Mellitus, Type 2 | 08/10 | 08/10 | | |
|
|
|
NCT01156597: Effects of Pioglitazone on High-density Lipoprotein (HDL) Function in Persons With Diabetes |
|
|
| Completed | 3 | 30 | US | pioglitazone, ACTOS | University of Miami, Takeda Pharmaceuticals North America, Inc. | Type 2 Diabetes Mellitus | 09/10 | 09/10 | | |
NCT00722371: MK0431 and Pioglitazone Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-102 AM2) |
|
|
| Completed | 3 | 1615 | US | Sitagliptin phosphate, Januvia, Tesavel, Xelevia, Ristaben, Pioglitazone hydrochloride, Actos, Matching placebo to sitagliptin, Matching placebo to pioglitazone, Metformin | Merck Sharp & Dohme LLC | Type 2 Diabetes Mellitus | 10/10 | 03/11 | | |
| Completed | 3 | 756 | US, Canada, Europe, RoW | pioglitazone, taspoglutide | Hoffmann-La Roche | Diabetes Mellitus Type 2 | 11/10 | 11/10 | | |
| Completed | 3 | 484 | US, Canada, Europe, RoW | Lixisenatide (AVE0010), Placebo, Pen auto-injector, OptiClik®, Pioglitazone, Metformin | Sanofi | Diabetes Mellitus Type 2 | 06/11 | 06/11 | | |
|
|
NCT01026194: Efficacy and Safety Study of MP-513 in Combination With Thiazolidinedione in Patients With Type 2 Diabetes |
|
|
| Completed | 3 | 204 | Japan | Placebo / Teneli (Teneligliptin) + pio (pioglitazone), Teneli / Teneli + pio | Mitsubishi Tanabe Pharma Corporation | Type 2 Diabetes Mellitus | 06/11 | 06/11 | | |
NCT00849056: Safety and Efficacy of Albiglutide in Type 2 Diabetes |
|
|
| Completed | 3 | 310 | Europe, US, RoW | albiglutide, placebo | GlaxoSmithKline | Diabetes Mellitus, Type 2 | 11/11 | 01/13 | | |
|
|
NCT01289119: Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes |
|
|
| Completed | 3 | 506 | RoW | Alogliptin, SYR-322, Placebo to alogliptin, Metformin, Fortamet, Glucophage, Glumetza, Pioglitazone, Actos | Takeda | Diabetes Mellitus, Type 2 | 12/11 | 12/11 | | |
|
|
|
NCT00996658 / 2009-013289-20: Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone |
|
|
| Completed | 3 | 278 | US, Europe, RoW | Placebo, Linagliptin | Boehringer Ingelheim, Eli Lilly and Company | Diabetes Mellitus, Type 2 | 03/12 | | | |
|
|
NCT01106131: Efficacy and Safety of CKD-501 Versus Pioglitazone When Added to Metformin |
|
|
| Completed | 3 | 253 | RoW | CKD-501 0.5mg, Lobeglitazone, Pioglitazone 15mg | Chong Kun Dang Pharmaceutical | Type 2 Diabetes Mellitus | 04/12 | 11/12 | | |
NCT01210001 / 2009-016154-40: Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin |
|
|
| Completed | 3 | 499 | US, Canada, Europe, RoW | Placebo, BI 10773 | Boehringer Ingelheim, Eli Lilly and Company | Diabetes Mellitus, Type 2 | 04/12 | | | |
|
|
|
NCT00789750: Colesevelam as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus |
|
|
| Completed | 3 | 562 | US | Colesevelam, Welchol, Placebo, No drug, Pioglitazone, Actos | Daiichi Sankyo, Inc. | Type 2 Diabetes Mellitus | 07/12 | 07/12 | | |
|
|
NCT01095666: A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone |
|
|
| Completed | 3 | 1484 | RoW | Dapagliflozin, BMS-512148, Metformin, Glucophage®, Dapagliflozin Placebo, Pioglitazone | AstraZeneca, AstraZeneca, Bristol-Myers Squibb | Type 2 Diabetes | 03/13 | 03/13 | | |
NCT01894568: A Study Comparing Insulin Peglispro With Insulin Glargine as Basal Insulin Treatment |
|
|
| Completed | 3 | 388 | Japan, RoW | Insulin Peglispro, LY2605541, Insulin Glargine, Oral Antihyperglycemic Medications (OAMs), Sulfonylureas, Meglitinides, Dipeptidyl Peptidase-4 (DPP-IV) Inhibitors, Biguanides, α-Glucosidase Inhibitors, Pioglitazone | Eli Lilly and Company | Type 2 Diabetes Mellitus | 04/15 | 04/15 | | |
NCT00353587: Safety and Efficacy Study of Metaglidasen in Type 2 Diabetes in Patients Suboptimally Controlled on Insulin |
|
|
| Completed | 2/3 | 396 | US, RoW | MBX-102, Placebo, Actos | CymaBay Therapeutics, Inc. | Type 2 Diabetes | 11/07 | 11/07 | | |
